Circulating cell free DNA (ccfDNA) fragmentomics for early detection of colorectal carcinoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...
Researchers from the University of Washington and the University of Utah observed the DNA difference by analyzing fragments derived from human glioblastoma and hepatocellular carcinoma cells ...
What information could patients and providers learn from DNA found in a blood sample? An expert sat down with CURE to discuss ctDNA misconceptions. For patients with cancer, circulating tumor DNA ...
This study is led by Prof. Luo Huiyan and Prof. Xu Ruihua (Department of Medical Oncology, Sun Yat Sen University Cancer Center). Colorectal adenomas (CRAs) represent precancerous lesions that precede ...
ctDNA can predict breast cancer relapse up to 38 months before clinical signs, with 88.2% accuracy in relapsed patients. Presence of ctDNA is linked to shorter relapse-free and overall survival, ...
Circulating tumour DNA (ctDNA) monitoring identified patients with muscle-invasive bladder cancer who showed significantly longer disease-free survival and overall survival when treated with adjuvant ...
Colorectal cancer (CRC) is a major public health issue, with over 43,000 new cases and nearly 17,700 deaths annually in France. The overall survival rate is currently 63%. It is much higher for early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results